Unanswered questions in cancer-associated thrombosis.
anticoagulants
cancer
cancer-associated venous thromboembolism
direct oral anticoagulant
low molecular weight heparin
treatment
venous thromboembolism
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
02
05
2022
received:
07
04
2022
accepted:
10
05
2022
pubmed:
26
5
2022
medline:
24
8
2022
entrez:
25
5
2022
Statut:
ppublish
Résumé
Cancer-associated venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients with cancer. Treatment of cancer-associated VTE comes with a heightened risk of anticoagulant-related bleeding that differs by choice of anticoagulant as well as by patient- and disease-specific risk factors. Available data from randomized controlled trials and observational studies in cancer-associated VTE suggest that direct oral anticoagulants are effective, continuing anticoagulation beyond six months is indicated in those with active cancer and that patients who develop 'breakthrough' thrombotic events can be effectively treated. We review the evidence that addresses these key clinical questions and offer pragmatic approaches in individualizing care. While significant investigative efforts over the past decade have made impactful advances, future research is needed to better define the factors that contribute to anticoagulant-related bleeding and VTE recurrence, in order to aid clinical decision-making that improves the care of patients with cancer-associated VTE.
Substances chimiques
Anticoagulants
0
Heparin, Low-Molecular-Weight
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
812-825Informations de copyright
© 2022 British Society for Haematology and John Wiley & Sons Ltd.
Références
Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484-8.
Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Applied Thrombosis/Hemostas. 2006;12(4):389-96.
Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-53.
Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162(15):1729-35.
Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 Suppl):454S-545S.
Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490-505.
Imberti D, Agnelli G, Ageno W, Moia M, Palareti G, Pistelli R, et al. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER registry. Haematologica. 2008;93(2):273-8.
Khorana AA, McCrae KR, Milentijevic D, Fortier J, Nelson WW, Laliberte F, et al. Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. Res Pract Thrombos Haemostas. 2017;1(1):14-22.
Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, Terrenato I, Sperati F, et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev 2018;6:CD006650, 2019, CD006468.
Maraveyas A, Beyer-Westendorf J, Lee AY, Mantovani LG, De Sanctis Y, Abdelgawwad K, et al. Cancer-associated ThrOmboSIs - patient-reported OutcoMes with RivarOxaban (COSIMO) - baseline characteristics and clinical outcomes. Res Pract Thromb Haemost. 2021;5(8):e12604.
Picker N, Lee AY, Cohen AT, Maraveyas A, Beyer-Westendorf J, Mantovani LG, et al. Anticoagulation treatment in cancer-associated venous thromboembolism: assessment of patient preferences using a discrete choice experiment (COSIMO study). Thromb Haemost. 2021;121(2):206-15.
Investigators E, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-510.
Investigators E-P, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-97.
Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764-72.
Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-52.
Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015;13(12):2187-91.
Hokusai VTEI, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-15.
Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AY. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res. 2014;134(6):1214-9.
Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615-24.
Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an Oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017-23.
McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost. 2020;18(2):411-21.
Agnelli G, Becattini C, Meyer G, Munoz A, Huisman MV, Connors JM, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599-607.
Planquette B, Bertoletti L, Charles-Nelson A, Laporte S, Grange C, Mahe I, et al. Rivaroxaban vs Dalteparin in cancer-associated thromboembolism: a randomized trial. Chest. 2022;161(3):781-90.
Schrag D, Uno H, Rosovsky RP, Rutherford C, Sanfilippo KM, Villano JL, et al. The comparative effectiveness of direct oral anti-coagulants and low molecular weight heparins for prevention of recurrent venous thromboembolism in cancer: the CANVAS pragmatic randomized trial. J Clin Oncol. 2021;39(15):12020.
Louzada ML, Carrier M, Lazo-Langner A, Dao V, Kovacs MJ, Ramsay TO, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation. 2012;126(4):448-54.
Frere C, Farge D, Schrag D, Prata PH, Connors JM. Direct Oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated thromboembolism: 2021 updated meta-analysis of randomized controlled trials. Blood. 2021;138(Supplement 1):668.
Kraaijpoel N, Di Nisio M, Mulder FI, van Es N, Beyer-Westendorf J, Carrier M, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE cancer study. Thromb Haemost. 2018;118(8):1439-49.
Ageno W, Vedovati MC, Cohen A, Huisman M, Bauersachs R, Gussoni G, et al. Bleeding with apixaban and Dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thromb Haemost. 2021;121(5):616-24.
Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-74.
Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing GJ, et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):2247-59.
Streiff MB, Holmstrom B, Angelini D, Ashrani A, Elshoury A, Fanikos J, et al. Cancer-Associated Venous Thromboembolic Disease, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology 2022 [Available from: https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf
Carrier M, Blais N, Crowther M, Kavan P, Le Gal G, Moodley O, et al. Treatment algorithm in cancer-associated thrombosis: updated Canadian expert consensus. Curr Oncol. 2021;28(6):5434-51.
de Winter MA, Dorresteijn JAN, Ageno W, Ay C, Beyer-Westendorf J, Coppens M, et al. Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score. Thromb Haemost. 2021. Epub ahead of print. https://doi.org/10.1055/s-0041-1735251
Samuelson Bannow BT, Lee A, Khorana AA, Zwicker JI, Noble S, Ay C, et al. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(6):1246-9.
Carney BJ, Wang TF, Ren S, George G, Al Homssi A, Gaddh M, et al. Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study. Blood Adv. 2021;5(24):5546-53.
Donato J, Campigotto F, Uhlmann EJ, Coletti E, Neuberg D, Weber GM, et al. Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood. 2015;126(4):494-9.
Zwicker JI, Karp Leaf R, Carrier M. A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. J Thromb Haemost. 2016;14(9):1736-40.
Carney BJ, Uhlmann EJ, Puligandla M, Mantia C, Weber GM, Neuberg DS, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. J Thromb Haemost. 2019;17(1):72-6.
Leader A, Hamulyak EN, Carney BJ, Avrahami M, Knip JJ, Rozenblatt S, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. Blood Adv. 2020;4(24):6291-7.
Li A, Li MK, Crowther M, Vazquez SR. Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: a systematic review. Thromb Res. 2020;194:240-5.
Wang TF, Baumann Kreuziger L, Leader A, Spectre G, Lim MY, Gahagan A, et al. Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: communication from the ISTH SSC subcommittee on hemostasis and malignancy. J Thromb Haemost. 2021;19(8):2068-81.
Pharmaceuticals J. XARELTO: HIGHLIGHTS OF PRESCRIBING INFORMATION. Titusville, NJ: Janssen Pharmaceuticals; 2016.
Byon W, Nepal S, Schuster AE, Shenker A, Frost CE. Regional gastrointestinal absorption of apixaban in healthy subjects. J Clin Pharmacol. 2018;58(7):965-71.
Parasrampuria DA, Kanamaru T, Connor A, Wilding I, Ogata K, Shimoto Y, et al. Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule. J Clin Pharmacol. 2015;55(11):1286-92.
Stampfuss J, Kubitza D, Becka M, Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther. 2013;51(7):549-61.
Moik F, Posch F, Zielinski C, Pabinger I, Ay C. Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials. Res Pract Thromb Haemost. 2020;4(4):550-61.
Moik F, Colling M, Mahe I, Jara-Palomares L, Pabinger I, Ay C. Extended anticoagulation treatment for cancer-associated thrombosis-rates of recurrence and bleeding beyond 6 months: a systematic review. J Thromb Haemost. 2021;20:619-34.
Englisch C, Moik F, Ay C. Risk assessment for recurrent venous thromboembolism in patients with cancer. Thrombosis. Update. 2021;5:100080.
Lapébie F, Bura-Rivière A, Merah A, Bertoletti L, Monreal M. OC-15 risk factors of recurrence in cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a RIETE-based prospective study. Thromb Res. 2021;200:S15.
Mahe I, Plaisance L, Chapelle C, Laporte S, Planquette B, Bertoletti L, et al. Long-term treatment of cancer-associated thrombosis (CAT) beyond 6 months in the medical practice: USCAT, a 432-patient retrospective non-interventional study. Cancers (Basel). 2020;12(8):2256.
Chee CE, Ashrani AA, Marks RS, Petterson TM, Bailey KR, Melton LJ 3rd, et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood. 2014;123(25):3972-8.
Marshall A, Levine M, Hill C, Hale D, Thirlwall J, Wilkie V, et al. Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D trial (SELECT-D: 12m). J Thromb Haemost. 2020;18(4):905-15.
Napolitano M, Saccullo G, Malato A, Sprini D, Ageno W, Imberti D, et al. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the cancer-DACUS study. J Clin Oncol. 2014;32(32):3607-12.
Caiano L, Carrier M, Marshall A, Young AM, Ageno W, Delluc A, et al. Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2021;19(10):2468-79.
Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, Asensio-Cruz MI, Blasco-Esquivias I, Sanchez-Lopez V, et al. D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis. Br J Cancer. 2018;119(8):915-21.
Di Nisio M, van Es N, Carrier M, Wang TF, Garcia D, Segers A, et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE cancer study. J Thromb Haemost. 2019;17(11):1866-74.
Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, Asensio-Cruz M, Blasco-Esquivias I, Marin-Barrera L, et al. Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study. Thromb Res. 2017;157:90-6.
Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman MV, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN study. J Thromb Haemost. 2015;13(6):1028-35.
Schmidt RA, Al Zaki A, Desilet N, Szefer E, Ratnaweera N, Peterson E, et al. Patient characteristics and long-term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism. Thromb Res. 2020;188:106-14.
Riedl JM, Schwarzenbacher E, Moik F, Horvath L, Gantschnigg A, Renneberg F, et al. Patterns of thromboembolism in patients with advanced pancreatic cancer undergoing first-line chemotherapy with FOLFIRINOX or gemcitabine/nab-paclitaxel. Thromb Haemost. 2022;122(4):633-45.
Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496-520.
Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566-e81.
Streiff MB, Holmstrom B, Angelini D, Ashrani A, Elshoury A, Fanikos J, et al. Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(10):1181-201.
Abdulla A, Davis WM, Ratnaweera N, Szefer E, Ballantyne Scott B, Lee AYY. A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer. Thromb Haemost. 2020;120(4):702-13.
Posch F, Riedl J, Reitter EM, Crowther MJ, Grilz E, Quehenberger P, et al. Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-dimer analysis: a prospective study. J Thromb Haemost. 2020;18(6):1348-56.
Candeloro M, Guman NAM, Kraaijpoel N, Di Nisio M. Risk assessment models for thrombosis and anticoagulant-related bleeding in ambulatory cancer patients. Semin Thromb Hemost. 2021;47(8):972-81.
Pfaundler N, Limacher A, Stalder O, Mean M, Rodondi N, Baumgartner C, et al. Prognosis in patients with cancer-associated venous thromboembolism: comparison of the RIETE-VTE and modified Ottawa score. J Thromb Haemost. 2020;18(5):1154-61.
Tardy B, Picard S, Guirimand F, Chapelle C, Danel Delerue M, Celarier T, et al. Bleeding risk of terminally ill patients hospitalized in palliative care units: the RHESO study. J Thromb Haemost. 2017;15(3):420-8.
Larsen TL, Garresori H, Brekke J, Enden T, Froen H, Jacobsen EM, et al. Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up. J Thromb Haemost. 2022;20(5):1166-81.
van Dam LF, Dronkers CEA, Gautam G, Eckerbom A, Ghanima W, Gleditsch J, et al. Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis. Blood. 2020;135(16):1377-85.
Schaefer JK, Li M, Wu Z, Basu T, Dorsch MP, Barnes GD, et al. Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs. J Thromb Haemost. 2021;19(1):212-20.
Noble S, Matzdorff A, Maraveyas A, Holm MV, Pisa G. Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology. Haematologica. 2015;100(11):1486-92.
Elalamy I, Mahe I, Ageno W, Meyer G. Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant. J Thromb Haemost. 2017;15(5):848-57.
Mahe I, Chidiac J, Pinson M, Pinson M, Swarnkar P, Nelson A, et al. Patients experience of living with cancer associated thrombosis in France (Le PELICAN). Thromb Res. 2020;194:66-71.
Menapace LA, McCrae KR, Khorana AA. Predictors of recurrent venous thromboembolism and bleeding on anticoagulation. Thromb Res. 2016;140(Suppl 1):S93-8.
Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost. 2009;7(5):760-5.
Ihaddadene R, Le Gal G, Delluc A, Carrier M. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis. Thromb Res. 2014;134(1):93-5.
Schulman S, Zondag M, Linkins L, Pasca S, Cheung YW, de Sancho M, et al. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. J Thromb Haemost. 2015;13(6):1010-8.
Mahe I, Agnelli G, Ay C, Bamias A, Becattini C, Carrier M, et al. Extended anticoagulant treatment with full- or reduced-dose apixaban in patients with cancer-associated venous thromboembolism: rationale and design of the API-CAT study. Thromb Haemost. 2022;122(4):646-56. Epub ahead of print. https://doi.org/10.1055/a-1647-9896